Researchers conducted a small, early-stage study to check the safety of a drug called tafasitamab in Japanese patients with B-cell non-Hodgkin lymphoma (NHL). The study included 24 patients with different types of this blood cancer. They tested tafasitamab by itself and combined with other cancer drugs like lenalidomide and parsaclisib.
All 24 patients experienced side effects from the treatments. Common side effects included low blood cell counts, changes in liver tests, diarrhea, and nausea. Two patients had severe side effects that were linked to other drugs in the combinations, not to tafasitamab alone. Importantly, there were no serious or fatal side effects that the researchers considered to be caused by tafasitamab itself.
The main reason to be careful with these results is the very small number of patients. With only 24 people, it's hard to know how common or rare side effects might be in a larger group. This study was designed to look at safety first, not to see if the treatments were effective against the cancer.
Readers should understand this as a first step in testing these drug combinations. It provides initial information that the safety profile appears manageable in this group, but much larger and longer studies are needed to confirm these findings and to learn if the treatments are effective.